HS
RPTX

HighVista Strategies’s Repare Therapeutics RPTX Stock Holding History

HighVista Strategies’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-165,173
Closed -$778K – 154
2024
Q1 		$778K Hold
165,173
– – 0.28% 103
2023
Q4 		$1.21M Hold
165,173
– – 0.44% 77
2023
Q3 		$2M Hold
165,173
– – 0.92% 32
2023
Q2 		$1.75M Buy
165,173
+283
+0.2% +$2.92K 0.8% 36
2023
Q1 		$1.62M Hold
164,890
– – 1.32% 28
2022
Q4 		$2.43M Sell
164,890
-139,291
-46% -$2.08M 1.44% 22
2022
Q3 		$3.69M Buy
304,181
+151,581
+99% +$1.95M 2.11% 10
2022
Q2 		$2.13M Buy
152,600
+9,225
+6% +$109K 1.29% 24
2022
Q1 		$2.04M Buy
143,375
+99,878
+230% +$1.48M 1.3% 22
2021
Q4 		$917K Buy
43,497
+7,393
+20% +$174K 0.73% 52
2021
Q3 		$947K Buy
+36,104
New +$1.17M 0.63% 56

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HighVista Strategies's RPTX Position: Q2 2024 in Review

HighVista Strategies sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 165,173 shares — an estimated $778K sold.

HighVista Strategies first reported a position in RPTX in Q3 2021 and held it in 11 quarters. The position peaked at $3.69M in Q3 2022. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

  • HighVista Strategies reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HighVista Strategies sold 165,173 Repare Therapeutics shares in Q2 2024, an estimated $778K.
  • HighVista Strategies first reported a position in Repare Therapeutics in Q3 2021 and held it in 11 quarters.
  • HighVista Strategies's Repare Therapeutics position peaked at $3.69M in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.